Clinical trials
Infectious Disease clinical trials
Below are recruiting infectious disease clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06096857RecruitingPhase 2
Cardamom and topical bacteria cream for eczema
This study tests whether taking cardamom by mouth and applying a cream made from a harmless bacteria (Roseomonas) can help treat eczema (atopic dermatitis) in people age 2 and older.
Bethesda, MarylandAges 2–100 - NCT06102070Recruiting
Genetic study of severe infections
This study looks for genetic reasons why some people get very serious infections. If you or a family member has had a rare, severe infection, researchers will analyze your DNA to find genes that might make you more vulnerable.
Paris, Île-de-France RegionAges Any age - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Birmingham, AlabamaAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab after lung transplant
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
Phoenix, ArizonaAges 12–75 - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
Boston, MassachusettsAges 18–65 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Birmingham, AlabamaAges 13–20 - NCT06024421RecruitingPhase 1
Testing high doses of favipiravir in healthy volunteers
This study tests the safety and how the body processes very high doses of the antiviral drug favipiravir in healthy people. It helps find the highest dose that is still safe before testing in patients.
ParisAges 18–75 - NCT05947071RecruitingPhase 2
Higher-dose flu vaccine versus standard dose in child transplant patients
This trial compares a higher-dose flu vaccine to the standard dose in children who recently received a kidney, heart, and/or liver transplant. It aims to see which dose better protects children against influenza while checking for safety.
Stanford, CaliforniaAges 3–17 - NCT05972772RecruitingPhase 2/Phase 3
Test study drugs to clear rickettsia infections
This study tests antibiotics to help your body clear rickettsia-related illnesses like murine typhus or scrub typhus. It may help reduce symptoms and shorten how long you feel sick, based on how well the infection clears.
Vientiane, VientaineAges 18 years+ - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Birmingham, AlabamaAges 18–70 - NCT05813964RecruitingPhase 3
Event-driven HIV prevention pill for men who have sex with men
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
ParisAges 18 years+ - NCT05719441RecruitingPhase 2
Testing HIV antibodies plus early HIV treatment for possible remission
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
Birmingham, AlabamaAges 18–70 - NCT05719259Recruiting
Study on pneumonia from breathing machines in the ICU
This study watches patients in the intensive care unit (ICU) who are on a breathing machine (ventilator) to learn more about pneumonia that can happen from the machine. The goal is to understand how to better prevent and treat this infection.
TiranaAges 18 years+ - NCT05656365Recruiting
Study of genes and immunity in PFAPA and other tonsil problems
This study looks at genetic markers and immune system patterns in people with PFAPA (periodic fevers with mouth sores and throat/neck gland symptoms) or similar tonsil problems. It may help researchers understand why these conditions happen and how they might be better diagnosed or treated.
Washington D.C., District of ColumbiaAges 1 month–99 years - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT05652478RecruitingPhase 2
How HIV prevention drugs affect metabolism in healthy people
This study tests how certain HIV prevention drugs affect the body's metabolism (how it uses energy) in healthy people. It aims to understand side effects before these drugs are used more widely, which could help make future treatments safer.
Bethesda, MarylandAges 18–55 - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Baltimore, MarylandAges 18–65 - NCT05600920RecruitingPhase 1/Phase 2
Long-acting IL-7 drug trial for low CD4 immune cells
This Phase 1/2 study tests a long-acting IL-7 medicine to raise low CD4 immune cells in people with idiopathic CD4 lymphopenia. Because this is a dose-escalation study, the goal is to check safety and see if the treatment affects immune cell levels.
Bethesda, MarylandAges 18–75 - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05587894RecruitingPhase 2
Testing optimized COVID antiviral treatment in immunocompromised adults
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Bordeaux, BordeauxAges 16 years+ - NCT05580458RecruitingPhase 1/Phase 2
Shingles vaccine study for adults with well-controlled HIV
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Bethesda, MarylandAges 18 years+ - NCT05458700Recruiting
Study of complicated urinary tract infections
This study looks at complicated urinary tract infections (UTIs), which are infections in the urinary system that happen when there is an underlying issue like a urinary catheter, blockage, or other urinary tract problem. The trial aims to gather information to better understand and treat these infections.
Seville, SevillaAges 18 years+ - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05383742RecruitingPhase 2
Compare 6- vs 9-month treatment for tuberculous meningitis
This Phase 2 study tests whether a shorter, stronger 6-month set of medicines works as well as the usual 9-month regimen for tuberculous meningitis (TB infection in the covering of the brain/spinal cord). The goal is to improve outcomes while reducing treatment time and exposure.
Porto AlegreAges 15 years+
Hear when a new Infectious Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for infectious disease?
- Yes. Clin2 currently lists 260 recruiting infectious disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a infectious disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a infectious disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.